Mobile

A Phase 3, Open Label, Trial, Evaluating the safety, tolerability and Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Children Previously Partially Immunized with Preven...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-003631-21

A Phase 3, Open Label, Trial, Evaluating the safety, tolerability and Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Children Previously Partially Immunized with Prevenar

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the pneumococcal immune response induced by 13vPnC when measured 1 month after the infant dose of 13vPnC in Group 1.

Critère d'inclusion

  • Healthy infants

Liens